What is Biomea Fusion, Inc.'s earnings per share (EPS)?

Biomea Fusion, Inc. (BMEA) reported diluted earnings per share of -$1.18 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biomea Fusion, Inc. Financials

BMEA

FY2025 annual

Revenue Not reported for FY2025

Net Income -$61.8M +55.4% YoY

EPS (Diluted) -$1.18 YoY not available

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

This page shows Biomea Fusion, Inc. (BMEA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BMEA FY2025 2026-08-29

R&D-led development spending remains the core mechanic, with external financing supporting operations as the balance sheet becomes thinner.

FY2025 net loss narrowed to -$62.0M while operating cash flow improved to -$70.4M, a paired change consistent with lower spending rather than revenue-led operating leverage. R&D fell to $62.0M from $118.1M; with revenue unreported, the improvement says more about expenditure intensity than commercial scale.

Assets fell from $199.9M in FY2023 to $58.6M in FY2025, so the company is operating with a much smaller financial base. FY2025 liabilities of $29.0M were nearly equal to equity of $29.6M, reflected in a 1.0x debt-to-equity ratio and a thinner solvency cushion despite a 5.2x current ratio.

FY2025 financing inflow of $67.9M nearly offset operating cash flow of -$70.4M, showing that cash movement depended on outside funding rather than internally generated cash. Shares outstanding rose from 37.6M in FY2024 to 72.3M in FY2025 while financing stayed positive, linking that support with substantial equity issuance.

Financial Health Signals

Financial health score not available

Biomea Fusion, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Biomea Fusion, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Biomea Fusion, Inc. reported a net loss of $61.8M while operations used $70.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Biomea Fusion, Inc. reported an operating loss of $83.5M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$82.1M

YoY+42.3%

Biomea Fusion, Inc.'s EBITDA was -$82.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.3% from the prior year.

Net Income

-$61.8M

YoY+55.4%

Biomea Fusion, Inc. reported -$61.8M in net income in fiscal year 2025. This represents an increase of 55.4% from the prior year.

EPS (Diluted)

-$1.18

Biomea Fusion, Inc. earned -$1.18 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$55.8M

YoY-4.2%

5Y CAGR-2.0%

Biomea Fusion, Inc. held $55.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

72M

Biomea Fusion, Inc. had 72M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-209.1%

YoY+59.3pp

5Y CAGR-106.1pp

Biomea Fusion, Inc.'s ROE was -209.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 59.3 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$62.0M

YoY-47.5%

5Y CAGR+76.0%

Biomea Fusion, Inc. invested $62.0M in research and development in fiscal year 2025. This represents a decrease of 47.5% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

BMEA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BMEA quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19
R&D Expenses	N/A	$62.0M-47.5%	$118.1M+15.2%	$102.5M+63.5%	$62.7M+124.0%	$28.0M+662.6%	$3.7M+236.2%	$1.1M
SG&A Expenses	N/A	$19.3M-25.6%	$26.0M+10.2%	$23.6M+12.8%	$20.9M+53.0%	$13.7M+725.5%	$1.7M+1507.8%	$103K
Operating Income	N/A	-$83.5M+42.0%	-$144.1M-14.2%	-$126.1M-50.8%	-$83.6M-100.7%	-$41.7M-682.2%	-$5.3M-345.8%	-$1.2M
Interest Expense	N/A	$1.9M-67.1%	$5.6M-36.4%	$8.9M	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	N/A
Net Income	N/A	-$61.8M+55.4%	-$138.4M-18.1%	-$117.3M-43.3%	-$81.8M-96.9%	-$41.6M-680.7%	-$5.3M-344.4%	-$1.2M
EPS (Diluted)	-$0.29	-$1.18	-$3.83-11.3%	-$3.44-22.9%	-$2.80-60.9%	-$1.74	-$0.51	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$9.1M+0.2%	$9.1M	N/A	$14.4M-13.1%	$16.6M-27.6%	$22.9M-9.3%	$25.2M-7.4%	$27.2M
SG&A Expenses	$3.6M-0.8%	$3.7M	N/A	$4.2M-10.8%	$4.7M-30.9%	$6.8M+41.0%	$4.8M-28.9%	$6.8M
Operating Income	-$12.8M+0.1%	-$12.8M	N/A	-$20.8M+2.2%	-$21.3M+28.4%	-$29.7M+1.2%	-$30.1M+11.6%	-$34.0M
Interest Expense	$319K-25.8%	$430K	N/A	$4.4M+1323.3%	$309K-31.3%	$450K	N/A	$1.3M
Net Income	-$8.3M+32.9%	-$12.4M	N/A	-$16.4M+20.9%	-$20.7M+29.1%	-$29.3M+0.1%	-$29.3M+10.6%	-$32.8M
EPS (Diluted)	-$0.12+29.4%	-$0.17-163.0%	$0.27+200.0%	-$0.27+47.1%	-$0.51+36.3%	-$0.80+1.2%	-$0.81+11.0%	-$0.91

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

BMEA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BMEA quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$58.6M-26.7%	$79.9M-60.0%	$199.9M+54.6%	$129.3M-30.4%	$185.7M+197.0%	$62.5M	N/A
Current Assets	$58.0M-15.0%	$68.3M-61.9%	$179.2M+52.1%	$117.8M-33.3%	$176.6M+183.8%	$62.2M	N/A
Cash & Equivalents	$55.8M-4.2%	$58.3M-67.0%	$176.9M+58.1%	$111.9M-23.2%	$145.7M+136.2%	$61.7M+25713.8%	$239K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$16K	N/A
Total Liabilities	$29.0M+2.3%	$28.4M-7.6%	$30.7M+47.8%	$20.8M+200.0%	$6.9M-87.9%	$57.4M	N/A
Current Liabilities	$11.1M-48.8%	$21.7M-5.2%	$22.9M+19.7%	$19.1M+311.9%	$4.6M+186.4%	$1.6M	N/A
Total Equity	$29.6M-42.7%	$51.6M-69.5%	$169.2M+55.9%	$108.5M-39.3%	$178.8M+3358.8%	$5.2M+24714.3%	-$21K
Retained Earnings	-$449.0M-16.0%	-$387.3M-55.6%	-$248.8M-89.1%	-$131.6M-164.5%	-$49.7M-508.5%	-$8.2M	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$36.9M-20.5%	$46.4M-20.8%	$58.6M+6.1%	$55.2M-24.6%	$73.2M+32.9%	$55.1M-31.1%	$79.9M-27.6%	$110.4M
Current Assets	$36.4M-21.4%	$46.3M-20.2%	$58.0M+17.4%	$49.4M-23.5%	$64.7M+44.7%	$44.7M-34.6%	$68.3M-27.0%	$93.6M
Cash & Equivalents	$34.8M-22.1%	$44.7M-19.9%	$55.8M+19.7%	$46.6M-17.0%	$56.2M+56.8%	$35.9M-38.5%	$58.3M-33.7%	$88.0M
Total Liabilities	$24.7M-10.6%	$27.7M-4.7%	$29.0M-26.7%	$39.6M-13.3%	$45.7M+73.5%	$26.3M-7.2%	$28.4M-17.7%	$34.4M
Current Liabilities	$10.5M+12.8%	$9.3M-16.3%	$11.1M-28.7%	$15.6M-11.4%	$17.6M-11.3%	$19.8M-8.6%	$21.7M-21.4%	$27.6M
Total Equity	$12.1M-35.2%	$18.7M-36.7%	$29.6M+89.2%	$15.6M-43.2%	$27.5M-4.3%	$28.7M-44.3%	$51.6M-32.1%	$76.0M
Retained Earnings	-$469.8M-1.8%	-$461.5M-2.8%	-$449.0M+1.0%	-$453.7M-3.8%	-$437.3M-5.0%	-$416.5M-7.6%	-$387.3M-8.2%	-$357.9M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

BMEA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BMEA quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$47.2M	-$70.4M+41.3%	-$119.9M-24.1%	-$96.6M-54.8%	-$62.4M-76.1%	-$35.4M-694.8%	-$4.5M-248.6%	-$1.3M
Capital Expenditures	N/A	N/A	$362K-89.3%	$3.4M+227.2%	$1.0M-67.5%	$3.2M+6117.6%	$51K	N/A
Free Cash Flow	N/A	N/A	-$120.3M-20.3%	-$100.0M-57.6%	-$63.4M-64.3%	-$38.6M-756.1%	-$4.5M	N/A
Investing Cash Flow	N/A	N/A	-$362K+83.7%	-$2.2M-108.1%	$27.3M+182.0%	-$33.4M-65302.0%	-$51K	N/A
Financing Cash Flow	N/A	$67.9M+3971.0%	$1.7M-99.0%	$163.8M+13120.2%	$1.2M-99.2%	$153.2M+132.2%	$66.0M+4481.0%	$1.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$10.0M+14.1%	-$11.7M+16.3%	-$13.9M-20.7%	-$11.6M+39.9%	-$19.2M+25.1%	-$25.7M+14.5%	-$30.0M-19.0%	-$25.2M
Capital Expenditures	N/A	N/A	N/A	$0	$0	$0-100.0%	$82K-55.9%	$186K
Free Cash Flow	N/A	N/A	N/A	-$11.6M+39.9%	-$19.2M+25.1%	-$25.7M+14.7%	-$30.1M-18.4%	-$25.4M
Investing Cash Flow	$0-100.0%	$550K	N/A	$0	$0	$0+100.0%	-$82K+55.9%	-$186K
Financing Cash Flow	N/A	N/A	$23.1M+1074.4%	$2.0M-95.0%	$39.6M+1116.9%	$3.3M+687.4%	$413K+498.6%	$69K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BMEA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BMEA quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Return on Equity	-209.1%+59.3pp	-268.4%-199.1pp	-69.3%+6.1pp	-75.4%-52.1pp	-23.3%+79.8pp	-103.0%	N/A
Return on Assets	-105.5%+67.7pp	-173.2%-114.5pp	-58.7%+4.6pp	-63.3%-40.9pp	-22.4%-13.9pp	-8.5%	N/A
Current Ratio	5.23+2.1x	3.15-4.7x	7.84+1.7x	6.17-31.9x	38.08-0.4x	38.43	N/A
Debt-to-Equity	0.98+0.4x	0.55+0.4x	0.180.0x	0.19+0.2x	0.04-11.1x	11.10	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-68.6%-2.3pp	-66.3%	N/A	-105.0%-29.7pp	-75.4%+26.4pp	-101.8%-45.0pp	-56.8%-13.7pp	-43.2%
Return on Assets	-22.6%+4.2pp	-26.8%	N/A	-29.7%-1.4pp	-28.3%+24.8pp	-53.1%-16.5pp	-36.7%-7.0pp	-29.7%
Current Ratio	3.48-1.5x	4.98-0.2x	5.23+2.1x	3.18-0.5x	3.68+1.4x	2.25-0.9x	3.15-0.2x	3.39
Debt-to-Equity	2.04+0.6x	1.48+0.5x	0.98-1.6x	2.53+0.9x	1.66+0.7x	0.92+0.4x	0.55+0.1x	0.45

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Corbus Pharmaceu CRBP

$211.0M

Pyxis Oncology, Inc. PYXS

$270.2M

Kala Pharmaceuticals Inc KALA

$13.0M

Equillium EQ

$143.9M

Zentalis Pharmaceuticals, Inc. ZNTL

$356.0M

Where Biomea Fusion, Inc. Ranks

Frequently Asked Questions

Is Biomea Fusion, Inc. profitable?

No, Biomea Fusion, Inc. (BMEA) reported a net income of -$61.8M in fiscal year 2025.

What is Biomea Fusion, Inc.'s EBITDA?

Biomea Fusion, Inc. (BMEA) had EBITDA of -$82.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biomea Fusion, Inc.'s return on equity (ROE)?

Biomea Fusion, Inc. (BMEA) has a return on equity of -209.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Biomea Fusion, Inc.'s operating cash flow?

Biomea Fusion, Inc. (BMEA) recorded an outflow of $70.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Biomea Fusion, Inc.'s total assets?

Biomea Fusion, Inc. (BMEA) had $58.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Biomea Fusion, Inc. spend on research and development?

Biomea Fusion, Inc. (BMEA) invested $62.0M in research and development during fiscal year 2025.

How many shares does Biomea Fusion, Inc. have outstanding?

Biomea Fusion, Inc. (BMEA) had 72M shares outstanding as of fiscal year 2025.

What is Biomea Fusion, Inc.'s current ratio?

Biomea Fusion, Inc. (BMEA) had a current ratio of 5.23 as of fiscal year 2025, which is generally considered healthy.

What is Biomea Fusion, Inc.'s debt-to-equity ratio?

Biomea Fusion, Inc. (BMEA) had a debt-to-equity ratio of 0.98 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biomea Fusion, Inc.'s return on assets (ROA)?

Biomea Fusion, Inc. (BMEA) had a return on assets of -105.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Biomea Fusion, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Biomea Fusion, Inc. (BMEA) held $55.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $70.4M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Biomea Fusion, Inc.'s Piotroski F-Score?

Biomea Fusion, Inc. (BMEA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biomea Fusion, Inc.'s earnings high quality?

Biomea Fusion, Inc. (BMEA) reported a net loss of $61.8M while operations used $70.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biomea Fusion, Inc. cover its interest payments?

Biomea Fusion, Inc. (BMEA) reported an operating loss of $83.5M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.